Roche India MD Girish Telang On Modifying Business Plans In India According To The Environment: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Roche India Managing Director Girish Telang has two difficult issues to handle. On the one hand, Telang has to work closely with his global team to develop the market for Roche in India and at the same time he has to ably fend off objections raised for Roche products through contentious patent battles with Indian companies. In an interview with PharmAsia News, Dr Telang outlines his concerns and reveals how India is placed to take his company's plans forward.
You may also be interested in...
A Change Of Plans: Roche Teams Up With Emcure For Low-Cost Herceptin, Mabthera In India
The Swiss pharma has changed up its strategy in India in an effort to boost volumes.
India’s Supreme Court Directs Patent Office To Review Roche's Valcyte Before Jan. 31
MUMBAI - India's Supreme Court has directed the Controller General of Patents, Designs and Trade Marks to finalize the patent validity of Roche's Valcyte (valganciclovir) before Jan. 31, 2009. Roche had filed a special leave petition that contested the Madras High Court's earlier decision that directed the Indian patent office to review the product patent granted to Valcyte in 2007
Roche Gears Up To Launch Actemra; Lines Up More Clinical Research In India
MUMBAI - Unperturbed by the spate of patent litigations, Swiss drug maker Roche is planning to bring into India Actemra (tocilizumab), its biological therapy indicated for the treatment of rheumatoid arthritis in adults and children